-
Big news around the corner .Bioniche is ready to takeoff eom
-
Positive results is coming very soon .. Bioniche Has The Potential To Become The Next 10-Bagger .GLTA !!
Lowered dose BCG - so far so good - Bladder Cancer Support Forum
Re:Lowered dose BCG - so far so good 3 Months, 1 Week ago
Hi Alan
Bioniche is the sponsor of our Canadian bladder cancer network website.
www.cbcan.org
The trials are continuing in phase 111. Should have some preliminary results late this year.
Results comparing their product directly vs BCG will be a few years away.
Phase 111 trials are BCG refractory patients.
I can tell you that the people I know at Bioniche are extremely positive about their product.
When I hear more information I will post.
Ja
-
Good News .. Load up the truck before its too late !!!!
Additional Phase III clinical trial with Urocidin(TM) expected to commence in 2010
Press Release Source: Bioniche Life Sciences Inc. On Thursday August 19, 2010, 7:00 am
- analysis of data from first Phase III clinical trial nearing completion -
BELLEVILLE, ON, Aug. 19 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC - News), a research-based, technology driven Canadian biopharmaceutical company, today provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer - Urocidin(TM).
Bioniche and its development partner, Endo Pharmaceuticals Inc. (NASDAQ: ENDP - News), are in the process of finalizing a protocol for an additional clinical trial - expected to begin enrolling patients in 2010. Details of this new protocol, when finalized, will be made publicly available via the U.S. National Institutes of Health clinical trial registration service at Home - ClinicalTrials.gov.
"We're preparing to initiate a large study with Urocidin in the second half of this year that could become the pivotal study of this very interesting product to treat bladder cancer," said Dr. Ivan Gergel, Executive Vice President, Research and Development at Endo Pharmaceuticals Inc. "Urocidin is a novel treatment for refractory bladder cancer, which represents the type of innovative solutions we want to offer urologists and their patients."
Concurrently, 12-month data from the ongoing U.S. Food and Drug Administration (FDA) Phase III registration trial with Urocidin(TM) for non-muscle-invasive bladder cancer refractory to current therapy are undergoing thorough analysis. Endo expects to complete this process by the end of September, 2010.
In North America, bladder cancer is the fourth most common cancer in men and is in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year and 500,000 living patients have been affected. The cancers of many of the previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70 percent of bladder cancer patients have the non-muscle-invasive form of bladder cancer and, on appropriate regulatory approvals, might be eligible for multiple treatments with Urocidin(TM).
Non-muscle-invasive bladder cancer is a form of bladder cancer localized in the surface layers of the bladder that has not yet spread into the deeper muscle layer. This form of bladder cancer is treated predominantly by urologists using surgical resection and intravesical infusion therapy. Urocidin(TM) is an intravesical infusion therapy, administered via trans-urethral catheter into the bladder.
Under the licensing agreement, Bioniche received an up-front payment of US$20 million in July, 2009, and has the potential to receive a total of US$110 million in payments associated with the achievement of certain clinical, regulatory and commercial milestones. Three milestones have been achieved by the Company since November, 2009, for total proceeds of US$14 million. Future milestones will be announced as they are achieved and, with its exclusive manufacturing supply contract, Bioniche will also receive a net-sales-based revenue stream upon product approval.
-
Up 15% today ..the runup has just begun !!
Market cap of 80 mil$ is a big joke ..
Urocidin for bladder cancer is a real blockbuster
get in now before its too late .this stock is a lifetime opportunity .
Please do your own dd!!!!!!!
-
-
RALLLLYYYYYYYYYYYYYYYYYYYYYYY...DONT MISS THE BIG OPPORTUNITY .SEE YOU AT 6$+ VERY SOON !!
Investors Hub - Charts
-
Good News ...
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology - Yahoo! Finance
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology
Press Release Source: Bioniche Life Sciences Inc. On Wednesday August 25, 2010, 7:00 am
- potential animal health and human health applications for reduction of anxiety -
-
Bioniche is the next takeover candidate !!!!
Endo Pharmaceuticals Looks For Acquisitions - Yahoo! Finance
Endo Pharmaceuticals Looks For Acquisitions
On Friday August 27, 2010, 4:40 pm EDT
To broaden its product base, Endo has also done some in-licensing. In July, 2009, Endo acquired exclusive rights from Bioniche Life Sciences to develop and market phase-three drug Urocidin for bladder cancer in the U.S. with a global marketing option.
Having bought Penwest, Endo can now make all the decisions about Opana without consultation. It also won't need to pay Penwest the 22% in royalties that were part of the previous partnership deal.
-
NEW 52W HIGH woooohooooo.. MAJOR BREAKOUT COMING
Investors Hub - Charts
POSITIVE PHASE 3 RESULTS WILL PUSH THIS STOCK TO $6+ EASILY !! GOOD LUCK
-
BNC HITS NEW 52W HIGH ..Bioniche is still very very cheap ...GLTA
100% BUY Signal is Created
Barchart.com Stocks | BNC.TO Detailed Opinion | Bioniche Life Scie Com Npv Detailed Opinion
Good News Coming ...
PharmaTelevision Sept.22 20110
PharmaTelevision - PTV Guide
Bioniche: Graeme McRae on Bioniche's Newly Discovered Cancer Killing Bacteria
In this episode of PharmaTelevision News Review, Fintan Walton talks with Graeme McRae, CEO at Bioniche. Filmed at BioChicago 2010 in , USA, they discuss:
• Origins and focus of Bioniche
• Mechanism of action behind Bioniche's bladder cancer product
• Scope of the product
• Animal health products
• Drugs in food safety
• Reduction of chances of E-coli breakout
Should be interesting
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
Forum Rules
LinkBack URL
About LinkBacks
Reply With Quote